Entrada Therapeutics (TRDA) Return on Sales (2023 - 2025)
Historic Return on Sales for Entrada Therapeutics (TRDA) over the last 3 years, with Q3 2025 value amounting to 27.37%.
- Entrada Therapeutics' Return on Sales fell 266600.0% to 27.37% in Q3 2025 from the same period last year, while for Sep 2025 it was 1.68%, marking a year-over-year decrease of 19400.0%. This contributed to the annual value of 0.31% for FY2024, which is 3600.0% up from last year.
- Per Entrada Therapeutics' latest filing, its Return on Sales stood at 27.37% for Q3 2025, which was down 266600.0% from 22.12% recorded in Q2 2025.
- Entrada Therapeutics' Return on Sales' 5-year high stood at 0.81% during Q3 2023, with a 5-year trough of 27.37% in Q3 2025.
- Over the past 3 years, Entrada Therapeutics' median Return on Sales value was 0.27% (recorded in 2023), while the average stood at 4.65%.
- As far as peak fluctuations go, Entrada Therapeutics' Return on Sales surged by 20100bps in 2024, and later crashed by -266600bps in 2025.
- Over the past 3 years, Entrada Therapeutics' Return on Sales (Quarter) stood at 0.23% in 2023, then soared by 113bps to 0.03% in 2024, then plummeted by -92742bps to 27.37% in 2025.
- Its last three reported values are 27.37% in Q3 2025, 22.12% for Q2 2025, and 0.84% during Q1 2025.